Silvio Danese to Humans
This is a "connection" page, showing publications Silvio Danese has written about Humans.
Connection Strength
0.609
-
IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther. 2022 01; 22(1):17-29.
Score: 0.008
-
SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021 04; 18(4):211-213.
Score: 0.008
-
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. Am J Gastroenterol. 2020 10; 115(10):1719-1721.
Score: 0.007
-
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. J Crohns Colitis. 2020 Sep 16; 14(9):1330-1333.
Score: 0.007
-
The day after COVID-19 in IBD: how to go back to 'normal'. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):441-443.
Score: 0.007
-
COVID-19 and gastrointestinal symptoms: the dust has not settled yet. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10):877-878.
Score: 0.007
-
More on Covid-19 in Immune-Mediated Inflammatory Diseases. N Engl J Med. 2020 08 20; 383(8):796.
Score: 0.007
-
Protecting patients with IBD during the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2020 07; 5(7):639.
Score: 0.007
-
Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. Gastroenterology. 2021 01; 160(1):472-473.
Score: 0.007
-
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. Lancet Gastroenterol Hepatol. 2020 07; 5(7):631-632.
Score: 0.007
-
Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 05; 17(5):253-255.
Score: 0.007
-
Is It Crohn's Disease? Gastroenterology. 2020 Oct; 159(4):1244-1246.
Score: 0.007
-
Author response to: Covid-19-related pancreatic injury. Br J Surg. 2020 06; 107(7):e191.
Score: 0.007
-
Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience. Gut. 2020 06; 69(6):981-983.
Score: 0.007
-
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. Ann Intern Med. 2020 09 01; 173(5):405-407.
Score: 0.007
-
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2020 07; 18(8):1882-1883.
Score: 0.007
-
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol. 2019 10; 85(10):2244-2254.
Score: 0.007
-
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7.
Score: 0.007
-
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019 10; 68(10):1893-1899.
Score: 0.007
-
Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019 08; 4(8):643-654.
Score: 0.007
-
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2397-2415.
Score: 0.007
-
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
Score: 0.007
-
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. Dig Dis. 2019; 37(4):266-283.
Score: 0.006
-
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. Drugs Today (Barc). 2019 Feb; 55(2):95-105.
Score: 0.006
-
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Curr Med Chem. 2019; 26(2):280-287.
Score: 0.006
-
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. Curr Drug Targets. 2019; 20(13):1327-1338.
Score: 0.006
-
Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap? Curr Med Chem. 2019; 26(2):246-247.
Score: 0.006
-
Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. Curr Drug Targets. 2019; 20(13):1339-1348.
Score: 0.006
-
Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases. Curr Drug Targets. 2019; 20(13):1315-1316.
Score: 0.006
-
Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2018 Dec; 55(3):368-378.
Score: 0.006
-
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
Score: 0.006
-
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
Score: 0.006
-
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. J Crohns Colitis. 2018 11 09; 12(10):1257-1258.
Score: 0.006
-
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes. 2019; 10(2):149-158.
Score: 0.006
-
Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 09 15; 24(10):2106-2112.
Score: 0.006
-
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029.
Score: 0.006
-
Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. J Crohns Colitis. 2018 Aug 22; 12(suppl_2):S678-S686.
Score: 0.006
-
Review article: treating-to-target for inflammatory bowel disease-associated anaemia. Aliment Pharmacol Ther. 2018 09; 48(6):610-617.
Score: 0.006
-
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
Score: 0.006
-
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018 07; 27(7):595-599.
Score: 0.006
-
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:43-47.
Score: 0.006
-
The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:79-87.
Score: 0.006
-
Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment Pharmacol Ther. 2018 09; 48(5):507-522.
Score: 0.006
-
JAK inhibitors: Novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:89-93.
Score: 0.006
-
Can IL-23 be a good target for ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:95-102.
Score: 0.006
-
Infliximab biosimilar CT-P13 for inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):373-375.
Score: 0.006
-
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
Score: 0.006
-
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):316-322.
Score: 0.006
-
Vedolizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2018 03; 14(3):179-189.
Score: 0.006
-
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
Score: 0.006
-
Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply. Aliment Pharmacol Ther. 2018 02; 47(4):540-541.
Score: 0.006
-
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2019 01; 68(1):40-48.
Score: 0.006
-
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):454-465.
Score: 0.006
-
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):319-326.
Score: 0.006
-
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci. 2017 11; 62(11):2964-2965.
Score: 0.006
-
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. Aliment Pharmacol Ther. 2017 11; 46(9):903-905.
Score: 0.006
-
Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. J Crohns Colitis. 2017 Oct 01; 11(10):1258-1266.
Score: 0.006
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.006
-
Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017 12; 66(12):2179-2187.
Score: 0.006
-
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clin Pharmacol Ther. 2017 Oct; 102(4):633-641.
Score: 0.006
-
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. Gastroenterology. 2017 11; 153(5):1363-1377.e6.
Score: 0.006
-
Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017 Dec; 85:103-116.
Score: 0.006
-
IBD: To switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017 09; 14(9):508-509.
Score: 0.006
-
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis. 2017 Jul 01; 11(7):767-768.
Score: 0.006
-
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017 Jun 15; 18(6).
Score: 0.006
-
Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. Aliment Pharmacol Ther. 2017 06; 45(12):1554-1555.
Score: 0.006
-
Clinical development of biologicals and biosimilars - safety concerns. Expert Rev Clin Pharmacol. 2017 06; 10(6):567-569.
Score: 0.006
-
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease? Inflamm Bowel Dis. 2017 05; 23(5):E22-E23.
Score: 0.006
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.006
-
The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017 Apr; 16(4):437-443.
Score: 0.006
-
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 05; 45(9):1179-1192.
Score: 0.006
-
Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017 Mar; 11(3):203-214.
Score: 0.006
-
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. Expert Rev Clin Immunol. 2017 05; 13(5):457-467.
Score: 0.006
-
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Curr Pharm Des. 2017; 23(44):6759-6769.
Score: 0.006
-
In the Presence of Conceptual Heterogeneity, Results of Network Meta-analysis Comparing Therapies in Crohn's Disease Need to Be Interpreted With Caution. Gastroenterology. 2015 Jun; 148(7):1483-4.
Score: 0.005
-
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014 Nov; 8(11):1548-50.
Score: 0.005
-
Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013 Oct; 38(7):741-51.
Score: 0.004
-
IBD: of mice and men-shedding new light on IL-13 activity in IBD. Nat Rev Gastroenterol Hepatol. 2011 Mar; 8(3):128-9.
Score: 0.004
-
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005 Dec 14; 11(46):7227-36.
Score: 0.003
-
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005 Apr; 100(4):886-95.
Score: 0.002
-
Oncophone20 study: Patients' perception of telemedicine in the COVID-19 pandemic during follow-up visits for gynecological and breast cancers. Int J Gynaecol Obstet. 2021 Dec; 155(3):398-403.
Score: 0.002
-
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology. 2021 06; 160(7):2435-2450.e34.
Score: 0.002
-
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S815-S819.
Score: 0.002
-
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S798-S806.
Score: 0.002
-
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. Clin Gastroenterol Hepatol. 2020 11; 18(12):2689-2700.
Score: 0.002
-
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. Pharmacol Res. 2020 10; 160:105061.
Score: 0.002
-
Reply. Clin Gastroenterol Hepatol. 2020 12; 18(13):3055.
Score: 0.002
-
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):507-516.
Score: 0.002
-
Liver tests abnormalities in COVID-19: trick or treat? J Hepatol. 2020 11; 73(5):1275-1276.
Score: 0.002
-
A snapshot of the ongoing clinical research on COVID-19. F1000Res. 2020; 9:373.
Score: 0.002
-
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. Clin Gastroenterol Hepatol. 2020 09; 18(10):2366-2368.e3.
Score: 0.002
-
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 07; 69(7):1213-1217.
Score: 0.002
-
Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. Gastroenterology. 2020 Jul; 159(1):14-19.e3.
Score: 0.002
-
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020 08; 18(9):2134-2135.
Score: 0.002
-
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol. 2020 06; 5(6):598-606.
Score: 0.002
-
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020 07; 18(8):1663-1672.
Score: 0.002
-
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019 Dec 10; 13(12):1569-1577.
Score: 0.002
-
Time to include patients with ulcerative proctitis in clinical trials. Lancet Gastroenterol Hepatol. 2019 12; 4(12):900-902.
Score: 0.002
-
Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? Dig Dis Sci. 2019 11; 64(11):3035-3037.
Score: 0.002
-
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1361-1369.
Score: 0.002
-
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214.
Score: 0.002
-
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1215-1226.
Score: 0.002
-
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
Score: 0.002
-
Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):26-31.
Score: 0.002
-
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
Score: 0.002
-
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1.
Score: 0.002
-
Big data in IBD: a look into the future. Nat Rev Gastroenterol Hepatol. 2019 05; 16(5):312-321.
Score: 0.002
-
Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology. 2019 09; 157(3):647-659.e4.
Score: 0.002
-
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. J Crohns Colitis. 2019 Mar 30; 13(4):417-423.
Score: 0.002
-
Obstetric outcomes in patients who have undergone excisional treatment for high-grade cervical squamous intra-epithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2019 May; 236:210-213.
Score: 0.002
-
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019; 26(2):259-269.
Score: 0.002
-
Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets. 2019; 20(13):1356-1362.
Score: 0.002
-
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019 03; 51(3):327-334.
Score: 0.002
-
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018 Nov 09; 12(10):1180-1190.
Score: 0.002
-
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
Score: 0.002
-
Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. Gynecol Oncol. 2018 12; 151(3):449-452.
Score: 0.002
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.002
-
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors' reply. Aliment Pharmacol Ther. 2018 09; 48(5):575-576.
Score: 0.002
-
The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 09; 14(9):739-749.
Score: 0.002
-
Simplified laparoscopic sacropexy avoiding deep vaginal dissection. Int J Gynaecol Obstet. 2018 Nov; 143(2):239-245.
Score: 0.002
-
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. Dig Dis. 2018; 36(5):346-353.
Score: 0.002
-
Authors' Reply to Pires et al.: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes". Drugs. 2018 06; 78(8):853-855.
Score: 0.002
-
Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:103-109.
Score: 0.002
-
Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:17-25.
Score: 0.002
-
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
Score: 0.002
-
Ustekinumab in the management of Crohn's disease: Expert opinion. Dig Liver Dis. 2018 07; 50(7):653-660.
Score: 0.002
-
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018 Mar; 78(4):463-478.
Score: 0.002
-
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783.
Score: 0.002
-
The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119.
Score: 0.001
-
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology. 2018 04; 154(5):1334-1342.e4.
Score: 0.001
-
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789.
Score: 0.001
-
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Oct 27; 11(11):1317-1325.
Score: 0.001
-
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
Score: 0.001
-
Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017 Dec; 10(12):1363-1374.
Score: 0.001
-
E-health in inflammatory bowel diseases: More challenges than opportunities? Dig Liver Dis. 2017 Dec; 49(12):1320-1326.
Score: 0.001
-
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929.
Score: 0.001
-
Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017 Jul; 33(4):246-253.
Score: 0.001
-
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
Score: 0.001
-
Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. BioDrugs. 2017 Jun; 31(3):223-237.
Score: 0.001
-
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144.
Score: 0.001
-
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736.
Score: 0.001
-
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
Score: 0.001
-
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul; 153(1):77-86.e6.
Score: 0.001
-
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun. 2017 Jun; 80:10-27.
Score: 0.001
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
Score: 0.001
-
Laparoscopic Nerve-Preserving Sacropexy. J Minim Invasive Gynecol. 2017 Nov - Dec; 24(7):1075-1077.
Score: 0.001
-
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072.
Score: 0.001
-
JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017 07; 13(7):693-703.
Score: 0.001
-
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
Score: 0.001
-
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. Dig Liver Dis. 2017 Jun; 49(6):604-617.
Score: 0.001
-
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
Score: 0.001
-
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2017 04; 49(4):338-358.
Score: 0.001
-
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. J Crohns Colitis. 2015 Jul; 9(7):541-7.
Score: 0.001
-
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5.
Score: 0.001